newsfilter
← Latest News
GlobeNewswire·

Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2025 Results

Updated interim results from the Company's [212Pb]VMT-α-NET Phase 1/2a study supporting the therapy's compelling overall clinical profile at the 5 mCi dose were presented at the ESMO Congress 2025, NANETS and Triple